Section Arrow
CANF.NYSE-M
- Can-Fite BioPharma Ltd
Quotes are at least 15-min delayed:2025/09/03 20:33 EDT
Regular Hours
Last
 0.6618
-0.0004 (-0.06%)
Day High 
0.665 
Prev. Close
0.6622 
1-M High
0.7031 
Volume 
69.94K 
Bid
0.6605
Ask
0.67
Day Low
0.6602 
Open
0.6602 
1-M Low
0.6301 
Market Cap 
9.65M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.65 
20-SMA 0.67 
50-SMA 0.84 
52-W High 3.12 
52-W Low 0.6301 
Exchange NYSE-M 
Valuation Estimation
EPS (Current/Estimated)
--/-0.03
Enterprise Value
9.70M
Balance Sheet
Book Value Per Share
0.29
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
674.00K
Operating Revenue Per Share
0.05
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
PMNProMIS Neurosciences0.4574-0.0792-14.76%6.98PE
ADAPAdaptimmune Therapeutics plc0.0526-0.0052-9.00%-- 
CARMCarisma Therapeutics0.3699-0.0701-15.93%-- 
ETHZETHZilla Corporation2.52-0.15-5.62%-- 
STTKShattuck Labs1.28+0.27+26.73%-- 
Quotes are at least 15-min delayed:2025/09/03 20:33 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.